Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective.
OBJECTIVE
Ceftaroline, approved in Europe in 2012, has activity against methicillin-resistant Staphylococcus aureus (MRSA), with MIC90 values of 1-2 mg/L depending on geographical location. During a global 2010 surveillance programme, conducted prior to the European launch, 4 S. aureus isolates, out of 8037 tested, possessing ceftaroline MIC values of >2 mg/L were identified. The objective of this study was to characterize these four isolates to elucidate the mechanism of ceftaroline resistance.


METHODS
MIC determinations were performed using broth microdilution and whole genome sequencing was performed to enable sequence-based analyses.


RESULTS
The only changes in proteins known to be required for full expression of methicillin resistance that correlated with the ceftaroline MIC were in penicillin-binding protein 2a (PBP2a). Isolates with a ceftaroline MIC of 2 mg/L had a Glu239Lys mutation in the non-penicillin-binding domain whereas the four isolates with ceftaroline MIC values of 8 mg/L carried an additional Glu447Lys mutation in the penicillin-binding domain. The impact of these mutations was analysed using the known X-ray structure of S. aureus PBP2a and a model for ceftaroline resistance proposed. Analysis of the core genomes showed that the isolates with reduced susceptibility to ceftaroline were epidemiologically related.


CONCLUSIONS
Mutations in PBP2a can affect the activity of ceftaroline against MRSA. Although a rare event, based on surveillance studies, it appears a first-step change in the non-penicillin-binding domain together with a second-step in the penicillin-binding domain may result in elevation of the ceftaroline MIC to >2 mg/L.
Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA, USA richard.alm@astrazeneca.com.
Richard A
RA
Alm
Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA, USA.
Robert E
RE
McLaughlin
Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA, USA.
Veronica N
VN
Kos
JMI Laboratories, North Liberty, IA, USA.
Helio S
HS
Sader
Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA, USA.
Joseph P
JP
Iaconis
Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA, USA.
Sushmita D
SD
Lahiri
D019943:Amino Acid Substitution; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015373:Bacterial Typing Techniques; D001483:Base Sequence; D002511:Cephalosporins / Q000494:pharmacology*; D004269:DNA, Bacterial / Q000235:genetics; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D016680:Genome, Bacterial / Q000235:genetics; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D008958:Models, Molecular; D046915:Penicillin-Binding Proteins / Q000235:genetics* / Q000648:ultrastructure; D017422:Sequence Analysis, DNA; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology; D000097583:Ceftaroline
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004269:DNA, Bacterial; D046915:Penicillin-Binding Proteins; D000097583:Ceftaroline
MRSA; penicillin-binding proteins; resistance